Literature DB >> 8472606

Nationwide quality control trial on lymphocyte immunophenotyping and flow cytometer performance in Italy.

B Brando1, E Sommaruga.   

Abstract

The Italian Society for Cytometry (Gruppo Italiano di Citometria, GIC) promoted this nationwide large-scale quality control trial on cellular immunophenotyping and flow cytometer performance in 1991. The aim of this independent study was to evaluate instrument performance with calibrated fluorescence microbeads (minimum threshold for FITC, linearity, coefficients of variation and resolution indexes for fluorescence), and to correlate it to the measurement of lyophilized lymphocyte surface immunofluorescence staining with a wide spectrum of antibodies (percentage of positive cells and fluorescence mean intensity). A single send-out was made to 306 laboratories with 350 instruments throughout Italy. Each kit included anonymous vials containing premixed calibrated microbeads, lyophilized human lymphocytes and small aliquots of conjugated monoclonal antibodies, for both single FITC and double FITC/PE staining. Participants were also asked to use their own anti-CD4 monoclonal. A valid answer was returned by 209 laboratories with 221 instruments. Gating was not an assay variable. The minimum sensitivity threshold for FITC ranged from 26.6 to 11,293 MESF, with marked instrument heterogeneity as far as the relationship between FITC threshold and coefficients of variation for fluorescence was concerned. A low FITC threshold also correlated with a good resolution index for low intensity stainings. No performance comparisons among instrument brands and models were made. The lyophilized lymphocyte analysis showed an overall frequency of outliers ranging from 3.2% to 19.7%, with a maximum for CD2 FITC (19.7%) and CD3 + HLA-DR + (12.1%). A strongly negative relationship was evident between the FITC threshold and the number of CD2+ cells, whereas the sensitivity threshold had virtually no effects on the measured level of higher antigen density markers like CD4 and many others. Absolute fluorescence intensity measurements of CD4+ and CD19+ were also made. This study design proved valid and suitable for a large-scale evaluation of both instrument performance and cytometer operators' skill. A number of practical problems were identified among participants, thus stressing the need for more effective educational programmes and technical guidelines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472606     DOI: 10.1002/cyto.990140310

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

1.  Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration.

Authors:  A Orfao; L Escribano; J Villarrubia; J L Velasco; C Cerveró; J Ciudad; J L Navarro; J F San Miguel
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

2.  The Italian quality control study for evaluation of CD4 cells in centres involved in the treatment of HIV-1 patients. Italian CD4 Quality Control Group.

Authors:  F Pandolfi; C Alario; E Girardi; L Rava; G Ippolito; A Kunkl; F Aiuti
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

3.  Atherosclerosis Risk in Communities (ARIC) Carotid MRI flow cytometry study of monocyte and platelet markers: intraindividual variability and reliability.

Authors:  Diane J Catellier; Nena Aleksic; Aaron R Folsom; Eric Boerwinkle
Journal:  Clin Chem       Date:  2008-05-29       Impact factor: 8.327

4.  Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample.

Authors:  Aaron R Folsom; Nena Aleksic; Antonio Sanhueza; Eric Boerwinkle
Journal:  Atherosclerosis       Date:  2008-11-18       Impact factor: 5.162

5.  The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.

Authors:  R H Rouce; H Shaim; T Sekine; G Weber; B Ballard; S Ku; C Barese; V Murali; M-F Wu; H Liu; E J Shpall; C M Bollard; K R Rabin; K Rezvani
Journal:  Leukemia       Date:  2015-12-01       Impact factor: 11.528

6.  External Quality Assessment on CD4+ T-Cell Count Using in-House Proficiency Testing Panels for CD4 Count Laboratories in Addis Ababa, Ethiopia.

Authors:  Natnael Kidanu Yibalih; Dawit Wolday; Samuel Kinde; Gebru Mulugeta Weldearegay
Journal:  Ethiop J Health Sci       Date:  2019-05

7.  Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring.

Authors:  Iole Macchia; Valentina La Sorsa; Irene Ruspantini; Massimo Sanchez; Valentina Tirelli; Maria Carollo; Giorgio Fedele; Pasqualina Leone; Giovanna Schiavoni; Carla Buccione; Paola Rizza; Paola Nisticò; Belinda Palermo; Stefania Morrone; Helena Stabile; Aurelia Rughetti; Marianna Nuti; Ilaria Grazia Zizzari; Cinzia Fionda; Roberta Maggio; Cristina Capuano; Concetta Quintarelli; Matilde Sinibaldi; Chiara Agrati; Rita Casetti; Andrea Rozo Gonzalez; Floriana Iacobone; Angela Gismondi; Filippo Belardelli; Mauro Biffoni; Francesca Urbani
Journal:  J Immunol Res       Date:  2020-04-12       Impact factor: 4.818

Review 8.  A Critical Review on the Standardization and Quality Assessment of Nonfunctional Laboratory Tests Frequently Used to Identify Inborn Errors of Immunity.

Authors:  Sandro Félix Perazzio; Patricia Palmeira; Dewton Moraes-Vasconcelos; Andréia Rangel-Santos; João Bosco de Oliveira; Luis Eduardo Coelho Andrade; Magda Carneiro-Sampaio
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

9.  The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.

Authors:  Hila Shaim; Zeev Estrov; David Harris; Mayra Hernandez Sanabria; Zhiming Liu; Peter Ruvolo; Phillip A Thompson; Alessandra Ferrajoli; May Daher; Jan Burger; Muharrem Muftuoglu; Nobuhiko Imahashi; Li Li; Enli Liu; Abdullah Saleh Alsuliman; Rafet Basar; Lucila Nassif Kerbauy; Catherine Sobieski; Elif Gokdemir; Kayo Kondo; William Wierda; Michael Keating; Elizabeth J Shpall; Katayoun Rezvani
Journal:  Front Immunol       Date:  2018-01-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.